(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Biden administration’s plan for high drug prices: “While we review the recently released Comprehensive Plan for Addressing High Drug Prices report,
(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s 100-day review of the actions needed to address vulnerabilities in our nation’s pharmaceutical supply chain and what measures need to be taken in order
In a new web video, Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott discusses the critical role and value of pharmacy benefit companies, the root cause of high prescription drug prices, and how solutions to boost competition, especially
Smoke and Mirrors Don’t let big drug companies’ smoke and mirrors fool you: High drug costs start and end with them. While pharmacy benefit companies are lowering costs, drug companies are busy blaming everyone in the supply chain but themselves
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
“PBMs promote competition in healthcare and help to reduce prices,” said Lawton Robert Burns Hot Off the Presses: University of Pennsylvania Wharton School professor Lawton Robert Burns releases a new book explaining the critical role pharmacy benefit companies play in
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the Administration’s listening session on PBMs. “Today’s White House listening session on PBMs, where policymakers only hear from people and groups with vocal anti-PBM agendas, will
Conversation on “Improving Competition to Lower Drug Prices” Emphasizes Need to Stop Abuse of the Patent System Last week, The Hill hosted an event titled, “Prescription for Change: Improving Competition to Lower Drug Prices.” During the event, lawmakers and a panel of drug
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S. Congress, explains the problem with misguided policies targeting pharmacy benefit companies in a new RealClearMarkets
©2024 PCMA. All Rights Reserved.
